Warning Letter Record: Stream2Sea, LLC (2026-02-02) — CGMP/Finished Pharmaceuticals/Adulterated
Letter issued · posted to fda.gov .
Subject as published: CGMP/Finished Pharmaceuticals/Adulterated
TL;DR
The short version: The FDA issued a warning letter (320-26-41, February 2, 2026) to Stream2Sea, LLC (FEI 3015234524) following a July 9-15, 2025 inspection, citing significant CGMP violations for finished pharmaceuticals that render products adulterated under 21 CFR parts 210-211 and the FD&C Act. Primary violations include: failure to perform adequate laboratory release testing (identity, strength, quality, purity) on finished drug product batches prior to distribution, with a specific example of a bulk batch manufactured October 3, 2024 that underwent additional processing December 23, 2024 without subsequent testing; and failure to conduct identity verification testing on raw material components and APIs, instead relying on supplier certificates of analysis without establishing a supplier qualification program. The FDA deemed Stream2Sea's August 5, 2025 response inadequate due to lack of detailed procedures, acceptance criteria specifics, and market impact assessment, and requested comprehensive remediation plans addressing laboratory system overhaul and incoming material testing protocols.
Argus analysis
# FDA Warning Letter Analysis: Stream2Sea, LLC
**Company and Findings**
Stream2Sea, LLC, a Bowling Green, Florida-based over-the-counter drug manufacturer, received a warning letter from FDA's Center for Drug Evaluation and Research on February 2, 2026, following an inspection conducted July 9–15, 2025. The agency determined that the company's drug products are adulterated because manufacturing methods, facilities, and controls fail to meet Current Good Manufacturing Practice standards. CEO and formulator Autumn P. Blum received the notice. The core concern: finished drug products were released for distribution without required testing and quality unit approval.
**Regulatory Citations and Implications**
Three major CGMP violations were cited. First, 21 CFR 211.165(a) requires finished drug batches to undergo laboratory testing for identity, strength, quality, and purity before release. Stream2Sea released products without this documentation. Second, 21 CFR 211.84(d)(1) and 211.84(d)(2) mandate identity testing of incoming components and periodic validation of supplier testing reliability; the company relied on supplier certificates of analysis without performing independent verification. Third, 21 CFR 211.67(b) requires written cleaning procedures and validation for shared equipment. Stream2Sea's cleaning documentation was inadequate and did not account for worst-case residue scenarios. These violations reflect foundational quality control gaps rather than isolated lapses.
**Response Timeline and Industry Monitoring**
Stream2Sea submitted a response to FDA's Form 483 on August 5, 2025, but it was deemed insufficient. The warning letter demands comprehensive corrective actions: independent laboratory system assessments, detailed testing specifications, supplier qualification programs, cleaning validation studies, and retrospective product impact assessments. FDA strongly recommends engaging a qualified consultant per 21 CFR 211.34. Compliance officers in the OTC drug sector should monitor whether Stream2Sea conducts announced follow-up inspections, voluntary recalls of distributed lots, or facility operational changes, as these typically signal regulatory progress.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
CGMP citations typically reference 21 CFR Part 211 (drugs) or 21 CFR Part 600 (biologics). Common subjects include identity testing of incoming components (211.84), validated cleaning procedures (211.67), and stability program design (211.166).
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Stream2Sea, LLC MARCS-CMS 718983 — February 02, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: Via Email Return Receipt Requested Reference #: 320-26-41 Product: Drugs Over-the-Counter Drugs Recipient: Recipient Name Ms. Autumn P. Blum Recipient Title CEO & Formulator Stream2Sea, LLC 2498 Commerce Ct. Bowling Green , FL 33834 United States (b)(4) Issuing Office: Center for Drug Evaluation and Research (CDER) United States Warning Letter 320-26-41 February 2, 2026 Dear Ms. Blum: The United States Food and Drug Administration (FDA) inspected your drug manufacturing facility, Stream2Sea, LLC, FEI 3015234524, located at 2498 Commerce Ct., Bowling Green, FL, from July 9 to 15, 2025. This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211). Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B). We reviewed your August 5, 2025, response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence. During our inspection, our investigators observed specific violations including, but not limited to, the following: 1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release (21 CFR 211.165(a)). Your firm failed to perform adequate analytical and microbiological release testing for each batch of your over the counter (OTC) drug products prior to distribution. For example, your “ (b)(4) ” batch (b)(4) , was manufactured on October 3, 2024. Samples were collected for pH, microbiological and assay testing between October 3 and October 7, 2024. Two months later, on December 23, 2024, this bulk batch underwent additional manufacturing by (b)(4) . No testing of the resulting final drug product, “ (b)(4) ” batch (b)(4) , was conducted. In addition, you released the same finished drug product batch prior to obtaining documented product release approval by the quality unit. Drug product batches must be tested for identity, strength, quality, and purity prior to release. Testing is an essential part of ensuring that the drug products you manufacture conform to all predetermined quality attributes and are appropriate for their intended use. Without adequate testing, you lack basic data to support that each drug product batch conforms to appropriate specifications before release. In your response, you acknowledge lack of understanding of the regulations. You commit to implement a comprehensive finis…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What FDA violations was Stream2Sea, LLC cited for?
- The FDA Warning Letter to Stream2Sea, LLC (issuing office: Center for Drug Evaluation and Research (CDER)) cites: CGMP/Finished Pharmaceuticals/Adulterated. Classification: CGMP — Current Good Manufacturing Practice.
- When did FDA issue the warning letter to Stream2Sea, LLC?
- FDA issued the letter (MARCS-CMS 718983) on 2026-02-02 and posted it publicly on fda.gov on 2026-09-29.
- Is the FDA warning letter to Stream2Sea, LLC publicly available?
- Yes. The full verbatim letter is published at fda.gov. Argus HQ links directly to the source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/stream2sea-llc-718983-02022026.
- What does a "critical" severity rating mean for this letter?
- Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). Warning Letter Record: Stream2Sea, LLC (2026-02-02) — CGMP/Finished Pharmaceuticals/Adulterated. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-stream2sea-llc-2026-02-02-cgmp
"Warning Letter Record: Stream2Sea, LLC (2026-02-02) — CGMP/Finished Pharmaceuticals/Adulterated." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-stream2sea-llc-2026-02-02-cgmp.
Argus HQ Research. "Warning Letter Record: Stream2Sea, LLC (2026-02-02) — CGMP/Finished Pharmaceuticals/Adulterated." Digital Empire Holdings LLC. Accessed September 30, 2026. https://argushq.ai/fda/warning-letter/fda-wl-stream2sea-llc-2026-02-02-cgmp.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_stream2sea_llc_2026_02_02_cgmp_2026,
title = {Warning Letter Record: Stream2Sea, LLC (2026-02-02) — CGMP/Finished Pharmaceuticals/Adulterated},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-stream2sea-llc-2026-02-02-cgmp},
note = {Accessed: September 30, 2026}
}